You can login if you already have an account or register by clicking the button below.
Registering is free and all you need is a username and password. We never ask you for your e-mail.
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask | Ars Technica
'For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. '
'In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. '
'The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business. '
'While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow. '
'But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. '
view the rest of the comments →
[–] derram 0 points 2 points 2 points (+2|-0) ago
https://archive.fo/VjkjE :
'For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. '
'In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. '
'The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business. '
'While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow. '
'But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. '
This has been an automated message.